Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Genmab A/S
  6. Summary
    GMAB   DK0010272202

GENMAB A/S

(GMAB)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Copenhagen
06/07/2021 06/08/2021 06/09/2021 06/10/2021 06/11/2021 Date
2509(c) 2531(c) 2607(c) 2629(c) 2649(c) Last
85 292 144 626 159 211 130 773 147 358 Volume
+0.97% +0.88% +3.00% +0.84% +0.76% Change
More quotes
Financials
Sales 2021 7 662 M 1 248 M 1 248 M
Net income 2021 2 061 M 336 M 336 M
Net cash position 2021 15 169 M 2 470 M 2 470 M
P/E ratio 2021 87,4x
Yield 2021 -
Sales 2022 10 031 M 1 633 M 1 633 M
Net income 2022 3 159 M 514 M 514 M
Net cash position 2022 17 611 M 2 868 M 2 868 M
P/E ratio 2022 57,2x
Yield 2022 -
Capitalization 173 B 28 174 M 28 191 M
EV / Sales 2021 20,6x
EV / Sales 2022 15,5x
Nbr of Employees 871
Free-Float 95,1%
More Financials
Company
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (46.9%); - licences (45.4%) ; - income from research and development (3.4%); - other (4.3%): primarily income from partnership agreement. At the end of 2020, the group had a... 
Sector
Biotechnology & Medical Research
Calendar
08/11 | 11:00amEarnings Release
More about the company
Ratings of Genmab A/S
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about GENMAB A/S
06/11GENMAB A/Sá : Investor Presentation - June 2021
PU
06/10GENMAB A/Sá : Transactions with shares and linked securities in Genmab A/S made ..
PU
06/10GENMAB A/Sá : Transactions with shares and linked securities in Genmab A/S made ..
AQ
06/10PRESS RELEASE : Pfizer and BioNTech to Provide 500 -3-
DJ
06/08GENMAB A/Sá : - Transactions in connection with share buy-back program
AQ
06/07GENMAB A/Sá : Transactions in connection with share buy-back program (Form 6-K)
PU
06/07GENMAB A/Sá : Transactions in connection with share buy-back program
AQ
06/02BOLT BIOTHERAPEUTICSá : Genmab Form Oncology Research and Development Collaborat..
MT
06/02GENMAB A/Sá : Bolt Biotherapeutics Partner to Develop Candidate Drugs Against Ca..
MT
06/02GENMAB A/Sá : and Bolt Biotherapeutics Announce Oncology Research and Developmen..
AQ
06/02PRESS RELEASE : CureVac Appoints Klaus Edvardsen as Chief Development Officer
DJ
06/01GENMAB A/Sá : Transactions in connection with share buy-back program (Form 6-K)
PU
06/01GENMAB A/Sá : to Participate in a Virtual Fireside Chat at the Goldman Sachs 42n..
AQ
05/28PRESS RELEASE : Pfizer and BioNTech Receive First -2-
DJ
05/25GENMAB A/Sá : Transactions in connection with share buy-back program (Form 6-K)
PU
More news
News in other languages on GENMAB A/S
06/10GlobeNewswire/Pfizer und BioNTech stellen der -4-
05/28GlobeNewswire/Pfizer und BioNTech erhalten erste -3-
05/21GlobeNewswire/BioNTech veröffentlicht ersten -2-
05/20GlobeNewswire/Pfizer und BioNTech unterzeichnen -3-
05/20GlobeNewswire/Pfizer und BioNTech beliefern die -3-
More news
Analyst Recommendations on GENMAB A/S
More recommendations
Stock Trading Strategies
GENMAB A/S - 2020
The underlying trend is to the upside
BUY
More Stock Trading Analysis
Chart GENMAB A/S
Duration : Period :
Genmab A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENMAB A/S
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 2 425,00 DKK
Last Close Price 2 649,00 DKK
Spread / Highest target 11,1%
Spread / Average Target -8,46%
Spread / Lowest Target -43,6%
EPS Revisions
Managers and Directors
NameTitle
Jan G. J. van de Winkel President & Chief Executive Officer
Anthony Pagano Chief Financial Officer & Executive Vice President
Deirdre P. Connelly Chairman
Tahamtan Ahmadi Chief Medical Officer & Executive Vice President
Anthony Mancini Chief Operating Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
GENMAB A/S7.55%28 174
GILEAD SCIENCES, INC.18.04%86 250
WUXI APPTEC CO., LTD.30.07%66 799
BIONTECH SE192.63%57 615
REGENERON PHARMACEUTICALS8.78%54 424
VERTEX PHARMACEUTICALS-18.33%49 966